Section Arrow
Quote
COEP.NASDAQ
- Coeptis Therapeutics Holdings Inc
Quotes are at least 15-min delayed:2025/11/16 06:47 EST
Regular Hours
Last
 14.555
+0.405 (+2.86%)
Day High 
14.8 
Prev. Close
14.15 
1-M High
16.5 
Volume 
10.78K 
Bid
13.6
Ask
14.95
Day Low
13.82 
Open
14.15 
1-M Low
13 
Market Cap 
68.21M 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 14.52 
20-SMA 14.85 
50-SMA 14.99 
52-W High 19.19 
52-W Low 2.31 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-6.87/-0.29
Enterprise Value
68.38M
Balance Sheet
Book Value Per Share
1.26
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
ASBPAspire Biopharma Holdings Inc.0.1063+0.0011+1.05%-- 
CYPHCypherpunk Technologies Inc.2.75+0.99+56.25%-- 
IVVDInvivyd2.35+0.58+32.77%-- 
APLTApplied Therapeutics0.2183-0.0517-19.15%-- 
RXRXRecursion Pharmaceuticals4.14-0.19-4.39%-- 
Quotes are at least 15-min delayed：2025/11/16 06:47 EST
Industry overview quotes are at least 15 minutes delayed
Business Description
Coeptis Therapeutics Holdings Inc is a biopharmaceutical company developing cell therapy platforms for patients with cancer. The company's product portfolio consists of multi-antigen CAR T technology licensed from the University of Pittsburgh (SNAP-CAR), a cell therapy technology (CD38-GEAR-NK), and an in vitro diagnostic (CD38-Diagnostic) targeting CD38-related cancers, which the company is developing with VyGen-Bio and medical researchers at the Karolinska Institutet.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.